Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 13/20 | 0.33 |
| ▸ | NPC1 | O15118 | 4/20 | 0.33 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3763783 | 0.75 | S1PR1 (0.39) | SMN1; SMN2NPC1RAB9AALDH1A1CYP1A2 | |
| SCHEMBL16804009 | 0.75 | SMN1; SMN2 (0.35) | SMN1; SMN2NPC1RAB9AALDH1A1CYP1A2 | |
| SCHEMBL14213304 | 0.74 | MEN1 (0.41) | SMN1; SMN2NPC1RAB9AALDH1A1TSHR | |
| SCHEMBL14213301 | 0.74 | MEN1 (0.41) | SMN1; SMN2NPC1RAB9AALDH1A1TSHR | |
| SCHEMBL14425145 | 0.67 | — | — | |
| SCHEMBL23651964 | 0.67 | SMN1; SMN2 (0.39) | SMN1; SMN2NPC1RAB9AALDH1A1CYP1A2 | |
| SCHEMBL468941 | 0.64 | — | — | |
| SCHEMBL85820 | 0.64 | GRM5 (0.44) | SMN1; SMN2NPC1RAB9AALDH1A1CYP1A2 | |
| SCHEMBL23189045 | 0.64 | CYP11B1 (0.39) | SMN1; SMN2NPC1RAB9AALDH1A1MAPK1 | |
| SCHEMBL25394987 | 0.63 | SMN1; SMN2 (0.34) | SMN1; SMN2NPC1RAB9AALDH1A1S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309750-A1 | 5-MEMBERED HETEROCYCLE DERIVATIVES AND MANUFACTURING PROCESS THEREOF | ILDONG PHARM CO., LTD. (KR) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309750-A1 | 5-MEMBERED HETEROCYCLE DERIVATIVES AND MANUFACTURING PROCESS THEREOF | CYP3A5, UGT2B7, UGT1A7 | SMN1; SMN2 1687/4885NPC1 2151/4885RAB9A 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.